Retinopathy of Prematurity Clinical Trial
Official title:
A 24-week, Open-label, Prospective, Single-arm Study Evaluating the Effectiveness and Safety of Lucentis® (Ranibizumab) 0.2mg in Retinopathy of Prematurity (ROP) Participants in China
This is a 24-week, multicenter, open-label, single-arm, observational, post approval commitment study, which is designed to collect effectiveness, safety and other clinical information of intravitreal ranibizumab 0.2 mg for the treatment of Retinopathy of Prematurity (ROP) participants in a real world clinical setting in mainland China.
Eligible participants treated according to local routine clinical practice will be enrolled in the study upon signing an Informed Consent. Participants will enter the study when they receive their first treatment and are followed up for 24 weeks. During the follow up period, participants could receive post-baseline treatment (i.e., ranibizumab or laser therapy) Patients will be treated according to the approved label and standard of care and as per Investigator judgement. End of study will be defined as completion of the week 24 visit or premature withdrawal visit ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05043077 -
Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening
|
Phase 4 | |
| Completed |
NCT04838665 -
Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study
|
Phase 4 | |
| Completed |
NCT04408807 -
Stress Induced by Screening for Retinopathy of Prematurity - Should Speculum and Indentation Rather be Avoided
|
N/A | |
| Recruiting |
NCT03083431 -
Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity
|
Phase 2 | |
| Enrolling by invitation |
NCT04985448 -
Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data
|
||
| Recruiting |
NCT02090322 -
Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1
|
N/A | |
| Completed |
NCT00872664 -
Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids
|
N/A | |
| Unknown status |
NCT00254176 -
Cysteine Supplementation in Critically Ill Neonates
|
Phase 2/Phase 3 | |
| Completed |
NCT04101721 -
Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
|
Phase 3 | |
| Enrolling by invitation |
NCT02050971 -
Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates
|
Phase 1 | |
| Terminated |
NCT01335113 -
A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity
|
||
| Active, not recruiting |
NCT00027222 -
The Early Treatment for Retinopathy of Prematurity Study (ETROP)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06109285 -
Validation of i-ROP DL to Detect More Than Mild ROP
|
N/A | |
| Completed |
NCT01861470 -
REDEXAM - Reducing Painful Eye Examinations in Preterm Infants
|
N/A | |
| Completed |
NCT02014454 -
Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature
|
Phase 2 | |
| Terminated |
NCT00634972 -
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
|
Phase 4 | |
| Completed |
NCT05701124 -
Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity
|
Phase 3 | |
| Completed |
NCT04092127 -
Pain of Premature Babies and RetCam (DOLICAM)
|
||
| Completed |
NCT04621136 -
PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity
|
Phase 1/Phase 2 | |
| Completed |
NCT04883931 -
Mother Milk as a Eye Drop & Premature Retinopathy
|
N/A |